Gated Miyokard Perfüzyon Spect Çalışmasındaki Stres Defekt Skorları İle Homosistein Düzeylerinin Karşılaştırılması

Year 2019, Volume: 11 Issue: 1, 69 - 75, 25.03.2019

Ayşe Yılmaz

https://doi.org/10.18521/ktd.432849

Abstract

Amaç: Ülkemizde
Koroner Arter Hastalığı (KAH) prevalansı giderek artmakta ve önemli sağlık
sorunlarından biri haline gelmektedir. GATED miyokard perfüzyon SPECT
sintigrafisi KAH tanısı koymada ve prognozu öngörmede kullanılan non-invaziv,
basit ve kolay bir tekniktir. Bu çalışmanın amacı GATED Miyokard Perfüzyon
SPECT çalışmasında elde ettiğimiz stres defekt skorları ile homosistein (HCY)
düzeyini karşılaştırmaktır.

Yöntem:
Kasım/2012-Mart–2013
tarihleri arasında KAH ön tanısı ile MPS için bölümümüze başvuran 166 hasta
çalışmaya dahil edildi. 96 kadın, 70 erkek (ortalama yaş 56±11,6) çalışma
grubunu oluşturdu. Hastalardan alınan kan örneklerinde ELISA metodu ile HCY
seviyesi ölçüldü. Görsel olarak iskemi varlığı değerlendirildi. Sol ventriküle
ait sayısal parametreler kantitatif GATED SPECT (QGS) yazılımı ile otomatik
olarak elde edildi.

Bulgular:
Hastalar
sintigrafi sonuçlarına göre 60 (%57,1)’ı normal, 45 (%42,9)’i iskemik olarak
bulundu. Hastaların HCY düzeyleri normal olan grupta 16,36±9,7 μmol/L
bulunurken, iskemik olan grupta 16,6±8,5 μmol/L bulundu (p=0,895).

Sonuç: Çalışmamızda
HCY düzeyi ile GATED miyokard perfüzyon SPECT çalışmasından elde ettiğimiz
kardiyovasküler risk parametreleri arasında anlamlı bir ilişki bulunmamıştır. 

Keywords

Koroner Arter Hastalığı, Homosistein, Myokard Perfüzyon Sintigrafisi

The Comparison of Homocysteine Levels with Stress Gated Myocardial Perfusion Defect Scores of the SPECT Study

Abstract

Objective: In our country, the prevalence of Coronary Artery Disease (CAD) has been
increasing and becoming one of the most important health problems. GATED SPECT myocardial perfusion scintigraphy is a
non-invasive, simple and easy technique used in diagnosis and predicting
prognosis of CAD. The aim of this study was to compare the level of
Homocysteine (HCY) with stress defect scores that we obtained from GATED
Myocardial Perfusion SPECT study.

Methods: Between November 2012-March 2013,
166 patients with suspected coronary artery disease referred to our department
for the myocardial perfusion scintigraphy included in this study. The study
consisted of 96 women and 70 men (mean age 56±11,6).
HCY levels were measured in blood samples by ELISA. The presence of ischemia was evaluated visually. The
numerical parameters of the left ventricle was obtained automatically by the software
quantitative gated SPECT (QGS).

Results: According to the
scintigraphic results, 60(%57,1)
of the patients were normal and 45(%42,9) of the patients had ischemia. Mean HCY values of
patients were found to be 16,36±9,7 μmol/L in normal group and 16,6±8,5 μmol/L in the ischemic group (p=0,895).

Conclusion: We found no significant correlation between HCY
levels and cardiovascular risk parameters obtained from GATED myocardial
perfusion SPECT.

Keywords

Coronary Artery Disease, Homocysteine, Myocardial Perfusion Scintigraphy

References

• Onat A, Şenocak MS. Türk Koroner Hastalarında Risk Faktörleri Sıklığı, Kümelenmesi ve Bunların Yol Açtığı Nisbi Risk. Türk Kardiyol Dern Arş 1992; 20:129-36.
• Eikelboom JW, Lonn E, Genest J et al. Homocysteine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. Ann Intern Med 1999;131:363-75.
• Harbert JC, Eckelman WC, Neumann RD (editors). Nuclear Medicine: Diagnosis and Therapy. New York. Thieme Medical Publishers; 1996; 23:445-81.
• La Rovere MT, Bigger JT Jr, Marcus FI et al. Baroreflex Sensitivity and Heart-Rate Variability in Prediction of Total Cardiac Mortality after Myocardial Infarction. ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators. Lancet 1998; 351:478–84.
• Hesse B, Tagil K, Cuocolo A, et al. EANM/ESC Procedural Guidelines for Myocardial Perfusion Imaging in Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2005; 32:855-97.
• Germano G, Kiat H, Kavanagh PB, et al. Automatic Quantification of Ejection Fraction from Gated Myocardial Perfusion SPECT. J Nucl Med 1995; 36: 2138–47.
• Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of Vascular Smooth Muscle Cell Growth by Homocysteine: A Link to Atherosclerosis. Proc Natl Acad Sci USA 1994: 91(14); 6369-73.
• Trabetti E. Homocysteine, MTHFR Gene Polymorphisms, and Cardio-cerebrovascular Risk. J Appl Genet. 2008;49(3):267-82.
• Wald DS, Law M, Morris JK. Homocysteine and Cardiovascular Disease: Evidence on Causality from a Meta-Analysis. BMJ 2002;325(7374):1202-6.
• Chai HT, Chen YL, Chung SY, et al. Value and Level of Plasma Homocysteine in Patients With Angina Pectoris Undergoing Coronary Angiographic Study. Int Heart J. 2011;52(5):280-5.
• Cho DY, Kim KN, Kim KM, et al. Combination of High-Sensitivity C-reactive protein and Homocysteine May Predict an Increased Risk of Coronary Artery Disease in Korean Population. Chin Med J (Engl). 2012;125(4):569-73.
• Ankrah A, Buscombe J, Sathekqe MM. Association Between Plasma Homocysteine and Myocardial SPECT Abnormalities in Patients Referred For Suspected Myocardial Ischemia. Cardiovasc J Afr 2012;23(6):313-7.
• Stempfer MJ, Malinow MR, Willett WC, et al. A Prospective Study of Plasma Homocysteine and Risk of Myocardial Infarction in US Physicians. JAMA 1992;268:877-81.
• Baños-González MA, Anglés-Cano E, Cardoso-Saldaña G, et al. Lipoprotein(a) and Homocysteine Potentiate The Risk of Coronary Artery Disease in Male Subjects. Circ J 2012;76(8):1953-7.
• Agoşton-Coldea L, Mocan T, Seicean A, et al. The Plasma Homocysteine Concentrations and Prior Myocardial Infarction. Rom J Intern Med 2010;48(1):65-72.
• Ghassibe-Sabbagh M, Platt DE, Youhanna S, et al. Genetic and Environmental Influences on Total Plasma Homocysteine and It’s Role in Coronary Artery Disease Risk. Atherosclerosis 2012;222(1):180-6.
• Xiao Y, Zhang Y, Lv X, et al. Relationship Between Lipid Profiles and Plasma Total Homocysteine, Cysteine and The Risk of Coronary Artery Disease in Coronary Angiographic Subjects. Lipids Health Dis. 2011;10(8): 137-44.